Active ingredientSulfinpyrazoneCat. No. P-S121-001CAS 57-96-5Family · Pharmaceutical analytical standards
Sulfinpyrazone
A uricosuric drug derived from pyrazolone, approved in the United States in 1959 for gout: it helps the kidneys eliminate uric acid by blocking its reabsorption. This family brings together the active ingredient and pharmacopoeial impurities.
Did you know?It also reduces platelet aggregation: for this reason, around 1980, it was studied in a large trial for prevention after a heart attack.
Go to the active ingredient →Active ingredientSulfinpyrazoneCat. No. P-S121-001CAS 57-96-5
Pharmacopoeial impuritySulfinpyrazone EP Impurity ACat. No. P-S121-002CAS 1106-50-9![1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dione](https://img.vitasanlabs.com/vsl-struct/P-S121-003.svg?v=41e934f030)
Pharmacopoeial impurity1,2-Diphenyl-4-[2-(phenylsulfanyl)-ethyl]pyrazolidine-3,5-dioneCat. No. P-S121-003CAS 3736-92-3No product matches your search.
EDQM standards 4
The official European Pharmacopoeia standards for this family.
Reference substanceSulfinpyrazone CRSEDQM code S2159000Family SulfinpyrazoneImpuritySulfinpyrazone impurity A CRSEDQM code S2159010Family SulfinpyrazoneImpuritySulfinpyrazone impurity B CRSEDQM code S2159015Family SulfinpyrazoneNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.